82 related articles for article (PubMed ID: 26185171)
1. Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin.
Nirmalanandhan VS; Hurren R; Cameron WD; Gronda M; Shamas-Din A; You L; Minden MD; Rocheleau JV; Schimmer AD
Haematologica; 2015 Oct; 100(10):e406-8. PubMed ID: 26185171
[No Abstract] [Full Text] [Related]
2. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.
De Toni F; Racaud-Sultan C; Chicanne G; Mas VM; Cariven C; Mesange F; Salles JP; Demur C; Allouche M; Payrastre B; Manenti S; Ysebaert L
Oncogene; 2006 May; 25(22):3113-22. PubMed ID: 16407823
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
4. In vitro induction of apoptosis and necrosis by new derivatives of daunorubicin.
Stojak M; Mazur L; Opydo-Chanek M; Lukawska M; Oszczapowicz I
Anticancer Res; 2013 Oct; 33(10):4439-43. PubMed ID: 24123013
[TBL] [Abstract][Full Text] [Related]
5. HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.
Wu J; Zhang L; Feng Y; Khadka B; Fang Z; Liu J
Biol Chem; 2021 Mar; 402(4):461-468. PubMed ID: 33938176
[TBL] [Abstract][Full Text] [Related]
6. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia.
Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC
Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843
[TBL] [Abstract][Full Text] [Related]
7. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay.
Möllgård L; Tidefelt U; Sundman-Engberg B; Löfgren C; Paul C
Leuk Res; 2000 May; 24(5):445-52. PubMed ID: 10785267
[TBL] [Abstract][Full Text] [Related]
8. Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
Masquelier M; Vitols S
Biochem Pharmacol; 2004 May; 67(9):1639-46. PubMed ID: 15081863
[TBL] [Abstract][Full Text] [Related]
9. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
10. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines.
Quillet-Mary A; Mansat V; Duchayne E; Come MG; Allouche M; Bailly JD; Bordier C; Laurent G
Leukemia; 1996 Mar; 10(3):417-25. PubMed ID: 8642856
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms.
Urasaki Y; Ueda T; Yoshida A; Fukushima T; Takeuchi N; Tsuruo T; Nakamura T
Anticancer Res; 1996; 16(2):709-14. PubMed ID: 8687117
[TBL] [Abstract][Full Text] [Related]
12. Marine benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill leukemia cells, but not cardiomyocytes.
Oftedal L; Selheim F; Wahlsten M; Sivonen K; Døskeland SO; Herfindal L
Mar Drugs; 2010 Oct; 8(10):2659-72. PubMed ID: 21116413
[TBL] [Abstract][Full Text] [Related]
13. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein.
Kartner N; Shales M; Riordan JR; Ling V
Cancer Res; 1983 Sep; 43(9):4413-9. PubMed ID: 6135505
[TBL] [Abstract][Full Text] [Related]
14. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
15. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
Côme MG; Skladanowski A; Larsen AK; Laurent G
Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
[TBL] [Abstract][Full Text] [Related]
16. In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells.
Dorlhiac-Llacer PE; Marquezini MV; Toffoletto O; Carneiro RC; Maranhão RC; Chamone DA
Braz J Med Biol Res; 2001 Oct; 34(10):1257-63. PubMed ID: 11593299
[TBL] [Abstract][Full Text] [Related]
17. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
[TBL] [Abstract][Full Text] [Related]
18. Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response.
Sheng X; Tucci J; Parmentier JH; Ji L; Behan JW; Heisterkamp N; Mittelman SD
Oncotarget; 2016 Nov; 7(45):73147-73159. PubMed ID: 27705905
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells.
Stuhldreier F; Kassel S; Schumacher L; Wesselborg S; Proksch P; Fritz G
Cancer Lett; 2015 May; 361(1):39-48. PubMed ID: 25697484
[TBL] [Abstract][Full Text] [Related]
20. Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation.
Pallis M; Russell NH
Br J Haematol; 1998 Jan; 100(1):194-7. PubMed ID: 9450811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
